HCW BIOLOGICS INC (HCWB)

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Mandatory press release to disclose receipt of Nasdaq Staff Determination Letter. ...

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules...

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

HCW Biologics signed license agreement with WY Biotech...

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Press release for Q3 2024 business highlights and financial results...

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

Results of Q2 2024, including settlement of long-running arbitration. ...

HCWB Stock Earnings: HCW Biologics Reported Results for Q2 2024

HCW Biologics just reported results for the second quarter of 2024.

HCWB Stock Earnings: HCW Biologics Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips HCW Biologics (NASDAQ:HCWB) just reported results for the second quarter of 202...

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

Results of Q2 2024, including settlement of long-running arbitration. ...

HCWB Stock Earnings: HCW Biologics Reported Results for Q1 2024

HCW Biologics just reported results for the first quarter of 2024.

HCWB Stock Earnings: HCW Biologics Reported Results for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips HCW Biologics (NASDAQ:HCWB) just reported results for the first quarter of 2024...

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

Earning release for Q1 2024...

HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023

HCWB stock results show that HCW Biologics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips HCW Biologics (NASDAQ:HCWB) just reported results for the fourth quarter of 202...

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Q4 and Year End Earnings Release and Business Highlights...

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights ...

Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors. ...

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

HCW9218 is the lead product candidate of HCW Biologics Inc.

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023...

HCW Biologics director Gary Winer buys shares worth $3.3k - filing (NASDAQ:HCWB)

HCW Biologics (HCWB) director Gary Winer disclosed in an SEC filing on Friday after the bell a purchase of 1,587 shares of the company at prices ranging from $2, $2.05, and $2.08 per...

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the...